H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $34.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ananda Ghosh’s rating is based on Maze Therapeutics’ promising developments in their clinical trials and innovative approach to treating PKU and CKD. The company’s use of the COMPASS platform and UK Biobank data has led to the identification of a significant genetic variant, which has informed the development of MZE782, a novel small-molecule inhibitor.
The confidence in Maze’s program is further supported by preclinical models showing MZE782’s effectiveness in increasing phenylalanine excretion and preserving kidney function, with minimal safety risks observed. Additionally, the ongoing Phase 1 trial and the anticipated Phase 2 studies are expected to validate the therapeutic potential of MZE782, reinforcing the Buy rating.
In another report released on August 7, Leerink Partners also maintained a Buy rating on the stock with a $28.00 price target.